Stryker (SYK) Q2 2026: Capital Backlog Drives 11% Second-Half Growth Target Amid Supply Disruption
Stryker’s Q2 revealed robust organic growth and margin recovery, but execution now hinges on a sizable production ramp to fulfill an elevated capital backlog. Leadership’s confidence in a double-digit second-half growth rate reflects both pent-up demand and operational risk, as supply chain normalization and salesforce stabilization remain critical. Investors should watch closely for margin durability and the pace of backlog conversion as Stryker navigates lingering vascular headwinds and a competitive innovation cycle.
Summary
- Capital Backlog Sets High Bar: Stryker’s production ramp is central to delivering on a double-digit second-half growth target.
- Margin Recovery Faces Moving Parts: Cyber event costs, tariff refunds, and supply disruptions complicate margin trajectory.
- Innovation Pipeline Remains Key: New launches and robotics expansion will be critical to sustaining outperformance.
Business Overview
Stryker is a global leader in medical technology, generating revenue through the development, manufacturing, and sale of devices and equipment for orthopedics, surgical, neurotechnology, and medical-surgical (med-surg) markets. Its major segments include MedSurg and Neurotechnology (covering surgical instruments, endoscopy, hospital infrastructure, and robotics), and Orthopedics (joint replacements, trauma, extremities, and spine). Stryker’s business model relies on both recurring procedural volume and capital equipment sales, with a growing emphasis on robotics and digital health solutions.
Performance Analysis
Stryker posted 9% organic sales growth in Q2, with both MedSurg and Orthopedics contributing high single-digit growth. The U.S. delivered 9% organic growth, led by double-digit gains in medical, trauma extremities, and endoscopy, while international markets posted a similar 8.9% organic increase, buoyed by strong results in Australia, Germany, and emerging markets. Adjusted EPS grew 17.9%, reflecting improved gross margins and a net tariff benefit, but also masking underlying volatility from the cyber incident and operational disruptions.
Segment dynamics revealed both resilience and vulnerability. MedSurg and Neurotechnology grew 9.2% organically, with standout performances in U.S. instruments (8.4%), endoscopy (10.2%), and medical (13.1%). However, vascular sales fell 6.7% due to a supply disruption in peripheral vascular, resulting in meaningful backorders and lost sales. Orthopedics grew 8.6% organically, with knee and hip sales up mid-single digits, and trauma and extremities up 12.5%. The Mako robotics platform continues to drive adoption, and recent launches in ankle and trauma are gaining traction.
- Capital Demand Surges: Elevated backlog and strong capital orders signal robust demand, but fulfillment depends on production ramping.
- Margin Expansion Supported by Tariff Refund: Gross margin improved 60 bps YoY, aided by a one-time tariff benefit and ongoing cost discipline.
- Vascular Supply Disruption Weighs: Peripheral vascular issues created backorders and will take until late Q3 to resolve, with some lost sales unrecoverable.
Cash flow remains robust, with $3.5B in cash and marketable securities and $1.8B in operating cash year-to-date. The company is resuming share repurchases, balancing M&A as its primary capital allocation priority.
Executive Commentary
"We have the orders to really drive very high growth. It's just how fast can we actually make everything to deliver? ... This is the best visibility that we have with what we know now. ... If things improve on a faster trajectory, then we could look to maybe move it up. But at this point, this is the best visibility that we have."
Kevin Lobo, Chair and Chief Executive Officer
"There are costs that are coming through from a cyber perspective, both with loss absorption from manufacturing, as well as there are IT costs that we have that we're planning for as we come through the remediation that will offset that benefit. So when you look at it on a half year basis, it actually, you can see those offsets already happening."
Preston Wells, Chief Financial Officer
Strategic Positioning
1. Capital Backlog and Production Ramp
Stryker’s ability to convert an elevated capital backlog into revenue is the central lever for hitting its narrowed guidance. The company’s guidance implies a required second-half organic growth rate near 11%. Management’s confidence rests on visible orders and the operational normalization of manufacturing after the Q1 cyber incident. However, execution risk remains around ramping shifts and resolving lingering supply chain disruptions, especially in MedSurg and peripheral vascular.
2. Innovation and Robotics Expansion
Innovation cadence remains a differentiator, with the Mako robotics platform marking 20 years and expanding into new specialties like spine and shoulder. The full commercial launch of Mako RPS and Triathlon Gold, along with new trauma and ankle systems, is intended to sustain procedural growth and competitive momentum. Early feedback on RPS is positive, particularly in ambulatory surgical centers (ASCs), a strategically important growth channel for joint replacement.
3. Margin Management and Cost Discipline
Margin expansion is supported by improved mix and cost control, but faces headwinds from cyber remediation costs and raw material inflation. The company reiterated its three-year, 150 bps operating margin expansion target, but acknowledged significant moving parts, including one-time tariff refunds and ongoing cyber-related expenses. SG&A leverage and manufacturing absorption will be key for margin durability.
4. Vascular Franchise Recovery
The peripheral vascular business remains a watchpoint after a plant-specific supply disruption caused backorders and lost sales. Management expects the backlog to normalize by Q3’s end, with full salesforce integration and new product launches (including IVL from the AVS acquisition) critical for recapturing growth and share in this high-potential segment.
5. Capital Allocation and Share Repurchase
Stryker is resuming share buybacks for the first time in six years, leveraging its strong cash flow and current sector valuation compression. M&A remains the top priority, but management has $1B authorized for repurchases, to be deployed opportunistically based on deal flow and share price.
Key Considerations
This quarter’s results and outlook reflect both Stryker’s operational resilience and the complexity of its recovery trajectory. The interplay between backlog fulfillment, margin management, and innovation cadence will define the next phase of performance.
Key Considerations:
- Backlog Conversion Pace: Fulfilling high capital orders depends on seamless production ramp, with any hiccup risking guidance miss.
- Margin Sustainability: Tariff refunds and cost discipline helped Q2, but recurring cyber and supply chain costs could pressure future quarters.
- Vascular Execution Risk: Peripheral vascular disruption demonstrates vulnerability in acquired businesses and integration processes.
- Innovation Adoption: Mako RPS and other launches must drive incremental growth to offset mature segment deceleration and reimbursement pressure.
- ASC Channel Growth: The ongoing shift to ambulatory surgical centers is a tailwind, but requires continued investment in channel-specific products and support.
Risks
Execution on the production ramp is the critical risk—any delay in manufacturing or fulfillment could undermine backlog conversion and growth targets. Supply chain normalization in vascular is not guaranteed, and lost sales may not be fully recoverable. Margin trajectory is clouded by cyber remediation costs, raw material inflation, and the one-time nature of tariff refunds. Reimbursement pressures and competitive innovation cycles, especially in orthopedics and robotics, remain ongoing threats to outperformance.
Forward Outlook
For Q3 and Q4, Stryker guided to:
- Organic net sales growth of 8.3% to 9.3% for the full year
- Adjusted net earnings per share of $14.95 to $15.10
Management highlighted:
- Elevated capital backlog and strong order book as drivers of second-half acceleration
- A steady cadence of new product launches, especially in robotics, trauma, and digital health
- Margin expansion commitment, but with caution due to cyber and supply chain costs
Takeaways
- Capital Fulfillment Is the Swing Factor: Stryker’s ability to convert backlog into revenue will determine if it meets or beats full-year guidance.
- Margin and Cash Flow Remain Strong: Cost discipline and tariff refunds supported Q2, but investors should monitor cyber cost drag and supply chain normalization.
- Innovation and Channel Shift Are Structural Levers: New robotics, trauma, and ASC-focused launches are necessary to offset reimbursement and competitive headwinds.
Conclusion
Stryker’s Q2 showcased the company’s operational resilience and breadth, but the path forward is defined by its ability to execute on a sizable production ramp and deliver on its capital backlog. Margin durability and innovation adoption will be critical for sustaining premium growth in a competitive medtech landscape.
Industry Read-Through
Stryker’s performance and commentary offer several signals for the broader medical technology sector. Robust capital demand and elevated backlogs suggest that hospital spending on equipment remains healthy, despite macro caution and procedure volume noise. However, the quarter also underscores the operational fragility of complex supply chains, especially following cyber events or integration challenges in acquired businesses. The continued expansion of robotics and digital health platforms, along with the steady migration of procedures to ASCs, points to enduring structural change. Competitors should anticipate ongoing pricing and reimbursement pressure in core orthopedics, while the importance of innovation cadence and channel-specific offerings will only intensify. Investors in medtech should closely monitor margin management tactics and the durability of capital order pipelines as key signals of sector health.